Latigo Biotherapeutics Completes IPO; Files Restated Certificate & Bylaws

What Happened
Latigo Biotherapeutics, Inc. announced that it completed its initial public offering (IPO) on August 10, 2026. The company sold 19,200,000 shares of common stock at $18.00 per share, generating approximately $345.6 million in gross proceeds. In connection with the IPO, Latigo filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, each made effective immediately prior to the IPO closing.

Key Details

• IPO date: August 10, 2026.
• Shares sold: 19,200,000 common shares at $18.00 per share.
• Gross proceeds: Approximately $345.6 million (before underwriting discounts, commissions and offering expenses).
• Corporate governance: Amended and restated certificate of incorporation and bylaws were approved by the board and stockholders and filed/implemented in connection with the offering; full texts are filed as Exhibits 3.1 and 3.2.

Why It Matters
The IPO provides Latigo with a significant infusion of capital that can support its operations, development programs, and growth plans. The amended and restated certificate and bylaws establish the company’s legal and governance framework as a newly public company. Investors should note the offering size and proceeds; other material financial details or forward-looking plans were not reported in this 8-K.